Current HIV/AIDS Reports

, Volume 2, Issue 4, pp 165–170 | Cite as

Managing HIV/AIDS in correctional settings

  • Sandra A. Springer
  • Frederick L. Altice
Article

Abstract

Approximately one quarter of people living with HIV/AIDS in the United States pass through the correctional system, resulting in a burden of infection on the correctional health care system that has challenged correctional and public health officials. The HIV epidemic behind bars results from the high prevalence of HIV risk behaviors among those incarcerated: illicit drug use, untreated mental illness, prostitution, homelessness, and poverty. Challenges to HIV care in correctional settings include management of comorbid conditions, remoteness from HIV care sites, organizational constraints, and access to effective therapies. Despite these challenges, prisoners with HIV have derived considerable benefit from HIV detection and treatment. In order to achieve parity in HIV outcomes among vulnerable populations, effective prison-release programs that incorporate effective case management with effective drug treatment and adherence strategies are required to extend the benefit of highly active antiretroviral therapy as prisoners transition back to community settings.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pollack HA, Khoshnood K, Altice FL: Health care delivery strategies for supervised offenders. J Health Care Finance 1999, 26:1–17.Google Scholar
  2. 2.
    Mumola CJ: Substance abuse and treatment of state and federal prisoners, 1997. Washington, DC: United States Department of Justice; 1999. [NCJ publication no. 172871.]Google Scholar
  3. 3.
    Hammett TM, Harmon MP, Rhodes W: The burden of infectious disease among inmates of and releasees from United States correctional facilities, 1997. Am J Public Health 2002, 92:1789–1794.PubMedCrossRefGoogle Scholar
  4. 4.
    National Commission on Correctional Health Care: The Health Status of Soon-to-be-Released Inmates. A Report to Congress. Chicago, IL: National Commission on Correctional Health Care; 2002. This report to Congress, commissioned through the National Commission on Correctional Health Care, provides a comprehensive analysis of infectious diseases and other conditions that negatively impact prisoners and its impact upon society after release.Google Scholar
  5. 5.
    Spaulding A, Stephenson B, Macalino G, et al.: Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis 2002, 35:305–312.PubMedCrossRefGoogle Scholar
  6. 6.
    Maruschak L: HIV in Prisons, 2000. Washington, DC: United States Department of Justice; 2002. [NCJ publication no. 196023.]Google Scholar
  7. 7.
    Marushak LM: HIV in Prisons and Jails, 2002. Washington, DC: United States Department of Justice; 2004. [NCJ publication no. 205333.]Google Scholar
  8. 8.
    AlticeFL, Mostashari F, Selwyn PA, et al.: Predictors of HIV infection among newly sentenced male prisoners. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:444–453. This, along with Altice et al. [9•], delineates, using a prospective analytic approach, the correlates of HIV infection among male and female prisoners, respectively.PubMedGoogle Scholar
  9. 9.
    AlticeFL, Marinovich A, Khoshnood K, et al.: Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection. J Urban Health 2005, 82:312–326.This, along with Altice et al. [8•], delineates, using a prospective analytic approach, the correlates of HIV infection among male and female prisoners, respectively.PubMedGoogle Scholar
  10. 10.
    Desai AA, Latta ET, Spaulding A, et al.: The importance of routine HIV testing in the incarcerated population: the Rhode Island experience. AIDS Edu Preview 2002, 14(Suppl 5B):45–52.CrossRefGoogle Scholar
  11. 11.
    Rosen DL, Golin CE, Schoenbach VJ, et al.: Availability of and access to medical services among HIV-infected inmates incarcerated in North Carolina county jails. J Health Care Poor Underserved 2004, 15:413–415.PubMedCrossRefGoogle Scholar
  12. 12.
    Paltiel AD, Weinstein MC, Kimmel AD, et al.: Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med 2005, 352:586–595.PubMedCrossRefGoogle Scholar
  13. 13.
    Estelle v Gamble, 429 US 97, 103,104 (1976).Google Scholar
  14. 14.
    World Health Organization: Guidelines on HIV Infection and AIDS in Prisons. Geneva: World Health Organization; 1993.Google Scholar
  15. 15.
    Gajewski-Verbanac L, Lewis SM, et al.: Retrospective analysis of antiretroviral treatment guidelines in a national correctional base [abstract 600]. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 1999:482.Google Scholar
  16. 16.
    Edwards S, Tenant-Flowers M, Buggy J, et al.: Issues in the management of prisoners infected with HIV: the King’s College Hospital HIV prison service retrospective cohort study. BMJ 2001, 322:398–399.PubMedCrossRefGoogle Scholar
  17. 17.
    Baillargeon J, Borucki MJ, Zepeda S, et al.: Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis 2000, 31:1476–1481.PubMedCrossRefGoogle Scholar
  18. 18.
    SpringerSA, Pesanti E, Hodges J, et al.: Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 2004, 38:1754–1760.This manuscript describes the impressive benefit of HAART among prisoners prescribed antiretroviral therapy, yet describes that this benefit is lost for many who do not receive effective discharge planning and effective drug treatment for relapse prevention.PubMedCrossRefGoogle Scholar
  19. 19.
    Fischl M, Castro J, Monroig R, et al.: Impact of directly observed therapy on long-term outcomes in HIV clinical trials [abstract 528]. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4–8, 2001.Google Scholar
  20. 20.
    Babudieri S, Aceti A, D’Offizi GP, et al.: Directly observed therapy to treat HIV infection in prisoners. JAMA 2000, 284:179–180.PubMedCrossRefGoogle Scholar
  21. 21.
    Wohl DA, Stephenson BL, Golin CE, et al.: Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis 2003, 36:1572–1576.PubMedCrossRefGoogle Scholar
  22. 22.
    Altice FL, Springer SA: Management of HIV/AIDS in correctional settings. In The AIDS Pandemic: Impact on Science and Society. Edited by Mayer KH. New York: Elsevier; 2005.Google Scholar
  23. 23.
    Altice FL, Buitrago MI: Adherence to antiretroviral therapy in correctional settings. J Correctional Health Care 1998, 5:179–200.Google Scholar
  24. 24.
    Shuter J: Communicable diseases in inmates; public health opportunities. In The Health Status of Soon-to-be-Released Inmates. Report to Congress National Commission on Correctional Health Care, Volume 2. Chicago, IL: National Commission on Correctional Health Care; 2002:167–202.Google Scholar
  25. 25.
    Sosman JM, Baker J, Catz SL, et al.: Clinical and immune recovery during antiretroviral therapy among HIV-infected prisoners. Presented at the XIV International AIDS Conference. Barcelona; July 7–12, 2002.Google Scholar
  26. 26.
    Altice FL, Mostashari F, Friedland GH: Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 28:47–58.PubMedGoogle Scholar
  27. 27.
    Mostashari F, Riley E, Selwyn PA, Altice FL: Acceptance and adherence with antiretroviral therapy among HIV-Infected women in a correctional facility. J AIDS Hum Retrovirol 1998, 18:341–348.Google Scholar
  28. 28.
    Blanco TM, Perez IB, March JC, et al.: Adherence to antiretroviral therapy among HIV-infected prison inmates (Spain). IntJSTD AIDS 2005, 16:133–138.CrossRefGoogle Scholar
  29. 29.
    Altice FL, Selwyn P, Watson RE, eds. Reaching. In Reaching Out: A Guide For The Correctional Professional. Chicago, Illinois; National Commission on Correctional Health Care Press: 2002.Google Scholar
  30. 30.
    Tomasino V, Swanson AJ, Nolan J, Shuman HI: The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. Mt Sinai J Med 2001, 68:14–20.PubMedGoogle Scholar
  31. 31.
    Dolan KA, Shearer J, MacDonald M, et al.: A randomized controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 2003, 72:59–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Smith-RohrbergD, Bruce RD, Altice FL: Review of corrections based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations. J Drug Issues 2004, 34:451–480.This article reviews the current practice of drug treatment in correctional settings and provides considerations for using buprenorphine in these settings.Google Scholar
  33. 33.
    Allen SA, Spaulding AC, Osei AM, et al.: Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003, 138:187–190.PubMedGoogle Scholar
  34. 34.
    Altice FL, Bruce RD: Hepatitis C virus infection in United States correctional institutions. Curr Hepa Repor 2004, 3:112–118.Google Scholar
  35. 35.
    Allen SA: Hepatitis C: The RI experience. Paper presented at the Management of Hepatitis C in Prisons Conference. San Antonio, Texas; January 25–26, 2003.Google Scholar
  36. 36.
    Beck AJ, Marushchak LM: Mental health treatment in state prisoners, 2000. Washington, DC: United States Department of Justice; 2000. [NCJ publication no. 188215.]Google Scholar
  37. 37.
    Veysey BM, Bichler-Robertson G: Prevalence estimates of psychiatric disorders in correctional settings. In The Health Status of Soon-to-be-Released Inmates. Report to Congress National Commission on Correctional Health Care, Volume 2. Chicago, IL: National Commission on Correctional Health Care; 2002:56–80.Google Scholar
  38. 38.
    Baillargeon J, Ducate S, Pulvino J, et al.: The association of psychiatric disorders and HIV infection in the correctional setting. Ann Epidemiol 2003, 13:606–612.PubMedCrossRefGoogle Scholar
  39. 39.
    Lucas GM, Gebo KA, Chaisson RE, Moore RD: Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002, 16:767–774.PubMedCrossRefGoogle Scholar
  40. 40.
    Bruce D, Altice FL: Editorial comment "Why treat three diagnoses when it is one patient? The AIDS Reader 2003, 13:378–379.PubMedGoogle Scholar
  41. 41.
    Wright LN, Smith PF: Decrease in AIDS-related mortality in a state correctional system—New York 1995–1999. MMWR Mort Morb Wkly Rep 1999, 47:1115–1118.Google Scholar
  42. 42.
    LazzariniZ, Altice FL: A review of the legal and ethical issues for the conduct of HIV-related research in prisons. AIDS Public Policy J 2000, 15:105–135.This article provides a comprehensive review of the legal and ethical considerations for providing HIV-related research among prisoners.PubMedGoogle Scholar
  43. 43.
    De Groot AS, Jackson EH, Stubblefield E: Clinical trials in correctional settings: proceedings of a conference held in Providence, Rhode Island, October 13–15, 1999. Med Health R I 2000, 83:376–379.PubMedGoogle Scholar
  44. 44.
    Palepu A, Tyndall MW, Chan K, et al.: Initiating highly active antiretroviral therapy and continuity of HIV care; the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther 2004, 9:713–719.PubMedGoogle Scholar
  45. 45.
    Richie BE, Freudenberg N, Page J: Reintegrating women leaving jail into urban communities: A description of a model program. J Urban Health 2001, 78:290–303.PubMedGoogle Scholar
  46. 46.
    Rich JD, Holmes L, Salas C, et al.: Successful linkage of medical care and community services for HIV-positive offenders being released from prison. J Urban Health 2001, 78:279–289.PubMedGoogle Scholar
  47. 47.
    Thompson AS, Blankenship KM, Selwyn PA, et al.: Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection. J Community Health 1998, 23:419–440.PubMedCrossRefGoogle Scholar
  48. 48.
    Bauserman RL, Richardson D, Ward M, et al.: HIV prevention with jail and prison inmates: Maryland’s Prevention Case Management program. AIDS Educ Prev 2003, 15:465–480.PubMedCrossRefGoogle Scholar
  49. 49.
    Gardner LI, Metsch LR, Anderson-Mahoney P, et al.: Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005, 19:423–431.PubMedCrossRefGoogle Scholar
  50. 50.
    Altice FL, Mezger JA, Hodges J, et al.: Developing a directly administered antiretroviral therapy intervention for HIV infected drug users: implications for program replication. Clin Infect Dis 2004, 38(Suppl 5):S376-S387.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Sandra A. Springer
    • 1
  • Frederick L. Altice
  1. 1.Yale AIDS Program, Section of Infectious DiseasesYale University School of MedicineNew HavenUSA

Personalised recommendations